glp-1 agonist alzheimer's Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus Repurposing glucagon-like peptide-1 receptor agonists

Analyses of medical records for people with diabetes or obesity have found a lower risk of AUD among those treated with a GLP-1

Findings from human islets and an in vivo T2D model suggest that these compounds may have the potential to improve T2D treatment

What's more, the GLP-1 Companion has high daily-to-monthly usage ratios, reflecting a level of engagement more on par with a social application than a behavior change program

There's no guarantee it will continue after 2027

Clinical Efficacy: Evidence from Major Trials Weight Loss Outcomes in Non-Diabetic Patients The clinical efficacy of GLP-1 agonists for weight loss in non-diabetic patients has been demonstrated across multiple large-scale randomized controlled trials

The study specifically highlighted that People with diabetes may have a lower risk of serious clots with GLP-1 drugs than with some other diabetes medications